The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients.
about
Molecular Genetic Markers in Acute Myeloid LeukemiaFLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsLong FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data.Investigational drugs targeting FLT3 for leukemia.The clinical development of FLT3 inhibitors in acute myeloid leukemia.Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others.Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia.Refining the prognostic importance of the diversity of FLT3 internal tandem duplications.Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort.Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloid Neoplasms.Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis of FLT3-ITD to detect patients with prognostically adverse AML.Clonal heterogeneity of -ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia
P2860
Q26799606-54CE3471-8AF7-4275-9A9E-317385EB7FBAQ28289859-CC7F6E3F-CD8B-441A-ABF2-A792F64F31A0Q33829079-3556E733-C57F-4CDA-9B57-B4B21FE78194Q34095013-046AA268-214D-40D6-8EE1-BAB9263720E0Q34295164-399FF6C5-6836-450F-B622-1F20CC718105Q37577934-FDA0B5C2-8A1D-4C1D-9867-B06C1C932F92Q37927089-03E31DBB-9B40-4017-935A-32A8B2ABFADCQ38183943-37E3E8BB-EEFC-49BE-BD5D-C1DFD125B257Q42349214-B87D781A-43E6-438C-A71F-57705E1DBB64Q45024752-CC8DF162-E9E7-4758-B27D-E69AA70083B9Q46122144-321C0E9C-6A6B-4D3E-A902-9C0B903AF818Q46576832-0E0B68FD-B911-444C-A002-5796CF6F74EDQ51200437-5EE331CF-1191-4B5D-BE15-85DA66D7137DQ54325426-1E4EBA61-850D-40F0-B7D3-BC3FEE2C4678Q56968572-05F02CD9-56EF-4B9C-9E43-E116B0C89FE2
P2860
The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
The size of duplication does n ...... ute myeloid leukemia patients.
@en
The size of duplication does n ...... ute myeloid leukemia patients.
@nl
type
label
The size of duplication does n ...... ute myeloid leukemia patients.
@en
The size of duplication does n ...... ute myeloid leukemia patients.
@nl
prefLabel
The size of duplication does n ...... ute myeloid leukemia patients.
@en
The size of duplication does n ...... ute myeloid leukemia patients.
@nl
P2093
P2860
P356
P1433
P1476
The size of duplication does n ...... ute myeloid leukemia patients.
@en
P2093
Antonioli E
Gianfaldoni G
Mannelli F
Ponziani V
Vannucchi AM
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404368
P577
2006-08-31T00:00:00Z
P5875
P6179
1018264205